EUVIMEDEUVIMED entdecken
Multizentrische Studie

A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents

Rachael Purcell, Daniel Yeoh iD, Asha Bowen iD, Philip N Britton, Jeremy P Carr, Ming Chen, Kaman Cheung, Julia Clark, Adam Irwin iD, Tony Lai iD, Ulrik Lorenzen, Andrew Steer und 5 weitere

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad131 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Rachael Purcell und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Royal Children's Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Fosfomycin, Urinary Tract Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urinary tract infections (UTIs) due to MDR organisms are increasingly common. The lack of paediatric data on efficacious antibiotics makes UTI treatment particularly challenging. Data on the efficacy of fosfomycin use for UTI in children are variable.

Methods

We conducted a retrospective audit of children aged 0–18 years who were treated with fosfomycin for UTI at seven tertiary paediatric hospitals in Australia over a 7 year period, from 2014 to 2020.

Results

Ninety-one children with a median age of 5 years (range 2 months to 18 years) received oral fosfomycin for UTI. The majority (57/91, 63%) had one or more comorbidity, with the most common being renal tract anomalies (24/91, 26%). Fifty-nine (65%) had febrile UTI, 14/91 (15%) had pyelonephritis and 1/91 (1%) was bacteraemic. A majority (80/91, 88%) of urinary cultures had an ESBL-producing Gram-negative pathogen isolated. Fosfomycin susceptibility was evident in all 80 isolates tested. For uncomplicated UTI, the most common dose in children aged <1, 1–12 and >12 years was 1, 2 and 3 g, respectively. For complicated UTI, doses of 2 and 3 g were most common. The median duration of fosfomycin administration was 5 days (range 1–82). Clinical cure was achieved in 84/90 (93%); the six with treatment failure had underlying comorbidities. Overall, 2/91 (2%) children experienced drug-related adverse effects comprising gastrointestinal symptoms in both, which resolved after treatment discontinuation.

Conclusions

Fosfomycin is well tolerated and associated with favourable treatment outcomes in children with UTI. Further research on the optimal dosing strategy is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FosfomycinUrinary Tract InfectionsHumansChildAdolescentInfantRetrospective StudiesAustraliaAnti-Bacterial Agents

Substanzen

FosfomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
  • Health Informatics Group, Murdoch Children's Research Institute, Melbourne, Australia.
  • Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
  • Bioinformatics Group, Centre for Health Analytics, Royal Children's Hospital, Melbourne, Australia.
  • Department of Infectious Diseases, Perth Children's Hospital, Perth, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

ORCID-Profile: Daniel Yeoh, Asha Bowen, Adam Irwin, Tony Lai

Zitieren

APA

Purcell, R., Yeoh, D., Bowen, A., Britton, P. N., Carr, J. P., Chen, M., Cheung, K., Clark, J., Irwin, A., Lai, T., Lorenzen, U., Steer, A., Wen, S., Williams, P., Yap, N., Cooper, C., & Gwee, A. (2023). A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad131

Vancouver

Purcell R, Yeoh D, Bowen A, Britton PN, Carr JP, Chen M, et al. A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad131

BibTeX
@article{Purcell2023,
  author = {Purcell, Rachael and Yeoh, Daniel and Bowen, Asha and Britton, Philip N and Carr, Jeremy P and Chen, Ming and Cheung, Kaman and Clark, Julia and Irwin, Adam and Lai, Tony and Lorenzen, Ulrik and Steer, Andrew and Wen, Sophie and Williams, Phoebe and Yap, Natalie and Cooper, Celia and Gwee, Amanda},
  title = {A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad131}
}
Kostenlos starten →